The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) in Baltimore offers a treatment for inoperable liver cancer known as Selective Internal Radiation Therapy (SIRT).
SIRT is a non-surgical outpatient therapy that uses radioactive microspheres, called SIR-Spheres®, to deliver radiation directly to the site of the liver tumors. This unique, targeted therapy spares healthy tissue while delivering up to 40 times more radiation to the liver tumors than would be possible using conventional radiotherapy.
Our physicians are very experienced at using microscopic beads to treat inoperable liver cancer. In 2000, UMGCC was the first center in the nation to successfully perform liver-directed therapy with TheraSpheres -- which used microscopic glass beads to deliver radiation to liver tumors. SIR-Spheres, developed by the Sirtex Medical, was approved by the U.S. Food and Drug Administration in 2002 for patients with primary colorectal cancer that has spread to the liver. It is the latest of a wide range of liver-directed therapies we offer to best meet our patients' needs.
Our multidisciplinary team of gastrointestinal cancer specialists hold weekly conferences to review each patient's records and determine the best treatment plan. The team includes surgeons, medical oncologists, radiation oncologists, radiologists, nuclear medicine physicians and pathologists, among others.
Our Liver Directed Therapies Program includes a full array of treatment options for patients with primary and metastatic liver cancer. In addition to SIRT and traditional surgery, chemotherapy and radiation approaches, these treatment options include:
While treatment with SIR-Spheres®, is generally not regarded as a cure, it has been shown to shrink liver cancer when combined with chemotherapy, more than chemotherapy alone. This can increase patients' life expectancy and improve their quality of life.
Learn more about SIRT: